Study drug plus lenvatinib for advanced small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests JS-201 combined with lenvatinib in people with extensive-stage small-cell lung cancer whose first-line treatment didn’t work. It may help by trying a new combination approach after prior therapy failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small-cell lung cancer on scans (not just limited-stage).
- Your first treatment with EC plus PD-L1 medicine did not work (treatment failure).
- Your performance status is 0 or 1, meaning you can do most self-care and are not significantly limited.
- Your diagnosis must be small-cell lung cancer, not non-small cell lung cancer.
- You are not currently pregnant (and can be required to use birth control if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.